Patent ID: 8198470
Filing Date: 2012-06-12
Classification: A61P,C07C

Abstract:
1. A crystalline tigecycline form II, characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 9.5, 9.8, 18.1, 20.2 and 21.6±0.2 degrees two-theta; a powder XRD spectrum as depicted in FIG. 1 ; a solid-state 13 C NMR spectrum with signals at 197.9, 149.1, 143.9, 115.2, and 106.0±0.2 ppm; a solid-state 13 C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift and another in the chemical shift range of 90 to 210 ppm of 98.1, 49.3, 44.1, 15.4, and 6.2±0.1 ppm wherein the signal exhibiting the lowest chemical shift in the chemical shift range of 90 to 210 ppm is at 99.8±1 ppm; a solid-state 13 C NMR spectrum depicted in FIG. 2 ; and a solid-state 13 C NMR spectrum depicted in FIG. 3 .